香港交易所及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不就本公告全部或任何部分內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 公告 二零二五年第三季度運營情況及二零二五年第四季度展望 安東油田服務集團（「本公司」，連同其附屬公司，合稱「本集團」）董事會（「董事 會」）欣然公告二零二五年七月一日至九月三十日之三個月（「本季度」）的運營情況 及在手訂單。 二零二五年第三季度運營概述 第三季度，國際油價寬幅震蕩，全球油氣投資保持活躍，中東地區持續推進產能 擴張。天然氣在發電與工業領域需求穩健增長，全球產業鏈機遇凸顯，項目開發 需求旺盛。 期內，本集團立足中國特色優勢與全球化布局，創新提出「技術服務作業者」戰略 定位，通過技術投入參與油氣資源獲取與開發，以「技術應用+自主開採+收益分 成」模式推進新業務落地。該模式有效強化公司業務競爭力，為未來突破性價值 增長奠定基礎。 二零二五年第三季度訂單情況 第三季度，本集團新增訂單人民幣1,272.9百萬元，較去年同期下降14.4%，其 中，伊拉克市場新增訂單約人民幣542.2百萬元，較去年同 ...

Core Insights - The third Asian Youth Games opened in Bahrain, featuring over 4,000 young athletes from 45 Asian countries, with Dafeng Industrial making a remarkable debut as the exclusive partner for the creative planning and implementation of the opening ceremony [1] - Dafeng Industrial has secured a ten-year exclusive partnership with the Olympic Council of Asia, becoming the sole partner for the creative planning and implementation of major events like the Asian Games and Asian Winter Games, marking a significant recognition of its capabilities [2] - The company is transitioning from equipment output to high-value services such as creative planning and standard concepts, aiming to become a global platform enterprise [5][6] Company Performance - In the first half of 2025, Dafeng Industrial achieved a revenue of 1.004 billion yuan, representing a year-on-year increase of 52.16%, and a total profit of 88.5911 million yuan, up 63.36% year-on-year [3] - The company is leveraging its core capabilities in planning, creativity, research and development, manufacturing, and operations to maintain its leading position in the cultural and sports tourism industry [3] Market Trends - The global tourism industry is expected to grow, with international tourism spending projected to reach a record $2.1 trillion by 2025 and $2.9 trillion by 2035, reflecting a compound annual growth rate of 3.4% [3] - China's tourism sector is anticipated to contribute 13.7 trillion yuan to the national economy by 2025, with an expected annual growth rate of 7%, double the overall economic growth rate [3] Strategic Developments - Dafeng Industrial is expanding its global footprint by leveraging its experience from the Hangzhou Asian Games, successfully securing the exclusive rights for the opening ceremony and torch system for the 2026 Aichi Nagoya Asian Games [4] - The company has established a strategic partnership with Zhiyuan Robotics to explore the intersection of humanoid robots and cultural tourism, aiming to enhance product value through innovative technology [4]

Core Viewpoint - Aucma is accelerating its international expansion by establishing a smart factory in Indonesia, which will produce 500,000 refrigerators annually, aligning with its globalization strategy and the Belt and Road Initiative [1][2]. Group 1: Investment and Production - The newly established Aucma smart factory in Indonesia will focus on smart manufacturing, producing household refrigeration and smart cold chain products using advanced technologies [1]. - The total planned investment for the Aucma Indonesia smart factory project is approximately 360 million yuan, with 10.91 million yuan already invested in the first half of the year [2]. - Upon completion, the factory is expected to fill the market gap for mid-to-high-end cold chain products in Indonesia and extend its reach to Southeast Asia and global markets [1][2]. Group 2: Financial Performance - In the first half of 2025, Aucma reported a revenue of 4.057 billion yuan and a net profit attributable to shareholders of 37.85 million yuan, with a significant increase of 28.47% in non-recurring net profit compared to the same period last year [2]. - The company is transitioning from a traditional home appliance manufacturer focused on freezers to a cold chain IoT enterprise, implementing an "Internet + Full Cold Chain" strategy [2]. Group 3: Market Strategy - Aucma is pursuing a dual-driven development strategy of OEM and its own brand, focusing on emerging markets in Southeast Asia, the Middle East, Africa, Latin America, and Central Asia [3]. - The company aims to deepen strategic cooperation with key global appliance customers in the European and American markets, achieving significant breakthroughs in the first half of the year [3].

Group 1 - Chery introduced a localized R&D concept at the 2025 Global Innovation Conference, emphasizing "In somewhere, For somewhere, Be somewhere" as a renewed approach to global innovation [2] - Chery's Chairman, Yin Tongyue, outlined the company's global development plans, highlighting that funds raised from its recent IPO will be primarily used for technology R&D and expanding overseas market operations [3][4] - Chery's overseas revenue is approaching half of its total revenue, with plans to increase local employee numbers and contributions in foreign markets [4] Group 2 - Chery has been a leader in China's automotive exports for 22 consecutive years, establishing a strong global presence and development capabilities [5] - The "Be somewhere" strategy aims to localize product development and brand presence, collaborating with local research institutions to address social issues and provide "Chinese solutions" [5][6] - Yin emphasized the importance of understanding both the Chinese and global perspectives in the company's international strategy [6] Group 3 - Chery's global strategy focuses on proactive measures, including regulatory compliance, adaptability to local fuel and infrastructure, differentiated market strategies, and enhancing product competitiveness [7] - The company engages local engineers for product testing in markets like Germany to ensure that vehicles meet local standards and consumer preferences [7][8] - Yin stressed the need for Chinese automakers to build relationships and avoid conflicts in foreign markets, ensuring sustainable development through local integration [8][9] Group 4 - The foundation of Chery's globalization is localized manufacturing, with a focus on providing local markets with tailored solutions through comprehensive planning in engineering, branding, and innovation [9]

Core Insights - The article highlights the rapid globalization of China's medical device industry, focusing on the company瑞迈特 (301367.SZ) as a leader in the home non-invasive ventilator and mask market, which is leveraging technological innovation and strategic positioning to break into international markets [1] Group 1: U.S. Market Developments - 瑞迈特's G3X model non-noise cotton ventilator has received FDA approval and completed medical reimbursement code registration, enabling it to enter the U.S. Medicare market starting July 2025 [2] - The U.S. is a key market for home non-invasive ventilators, and the reimbursement system significantly boosts product sales;瑞迈特's G3X product is expected to quickly capture market share in North America [2] - The company is implementing a dual-channel strategy in China, with online and offline sales to support its global expansion, ensuring stable cash flow for overseas market development [2] Group 2: European Market Strategy - 瑞迈特 has established a European respiratory data management cloud platform, facilitating the transition from non-mainstream to mainstream reimbursement markets in Europe [3] - The cloud platform integrates channel resources and patient data, enhancing product management and remote diagnosis capabilities, aligning with European healthcare demands for chronic disease management [3] - As agents connect to the platform, it is expected to generate continuous order growth and shift the company's focus from product sales to service offerings, increasing customer loyalty and long-term revenue potential [3] Group 3: Supply Chain and Product Structure - 瑞迈特 has achieved significant domestic supply chain localization, enhancing cost advantages and technical independence, which is crucial for international competition [4] - The company has a strong reputation in the respiratory health sector, providing comprehensive treatment solutions for patients with OSA and COPD, and is the first domestic company to receive FDA certification for non-invasive ventilators [4] Group 4: Market Position and Future Outlook - 瑞迈特's products are sold in over 100 countries, with a global market share of 12.4% and a domestic market share of 30.6%, ranking first among domestic brands [5] - The company is poised for growth in the context of an aging population and rising chronic respiratory diseases, with a strategic focus on the U.S. and European markets [5] - 瑞迈特's three-dimensional strategy of "product + service + localization" serves as a model for other Chinese medical device companies looking to expand internationally [5]

Core Viewpoint - The successful listing of BeBeBus's parent company, Different Group, on the Hong Kong Stock Exchange marks a new phase in its global development strategy, emphasizing innovation and unique user value for elite families [1] Group 1: Company Strategy - Different Group has adhered to the value proposition of "Creating Differences" since its establishment six years ago, focusing on technological innovation to enhance user experience for global elite families [1] - To support its globalization strategy, Different Group plans to upgrade its organizational capabilities and establish the "Different Technology Innovation Research Institute" to develop smart technology products for parent-child scenarios [1] Group 2: Future Plans - The company aims to build an overseas division to attract global talent in research and market development, providing strong support for its international expansion and creating a localized brand ecosystem [1] - Different Group will continue to enhance its innovation capabilities and organizational efficiency by deepening user insights, optimizing product development, and improving supply chain systems, moving towards becoming a "global elite family technology lifestyle company" [1]

Core Viewpoint - Sany Heavy Industry Co., Ltd. plans to issue approximately 580.42 million shares at a price range of HKD 20.3 to HKD 21.3, aiming to raise between HKD 117.83 billion and HKD 124.63 billion in its upcoming IPO on the Hong Kong Stock Exchange, scheduled for October 28, 2025 [1][3]. Company Overview - Sany Heavy Industry was founded in 1994, evolving from the Hunan Sany Heavy Industry Group Co., Ltd. and is headquartered in Beijing. The company has a registered capital of approximately RMB 8.475 billion [4]. - The company is primarily controlled by Sany Group, which holds about 33.73% of the total share capital prior to the IPO [3][4]. Financial Performance - For the years 2022, 2023, and 2024, Sany Heavy Industry reported revenues of approximately RMB 808.39 billion, RMB 740.19 billion, and RMB 783.83 billion, respectively. The gross profits for the same years were approximately RMB 182.96 billion, RMB 195.76 billion, and RMB 209.03 billion, with net profits of RMB 44.33 billion, RMB 46.06 billion, and RMB 60.93 billion [6][7]. - In the first four months of 2025, the company achieved revenues of approximately RMB 294.26 billion, a gross profit of about RMB 79.84 billion, and a net profit of around RMB 34.76 billion [7]. - For the first half of 2025, Sany Heavy Industry reported revenues of approximately RMB 445.34 billion, a 14.96% increase from the same period in 2024, and a net profit of approximately RMB 52.16 billion, reflecting a 46.00% year-on-year growth [8]. IPO Details - The IPO will involve 5.8042 billion shares, with a median offer price of HKD 20.80, leading to an estimated total fundraising of approximately HKD 120.73 billion and a net amount of about HKD 119.26 billion [1][3]. - Sany Heavy Industry has secured agreements with 23 cornerstone investors, who will collectively subscribe to shares worth approximately USD 758 million (around HKD 58.99 billion) [3].

Summary of the Conference Call for Innovent Biologics Company and Industry Overview - **Company**: Innovent Biologics - **Industry**: Biopharmaceuticals, specifically focusing on oncology therapies Key Points and Arguments 1. **Strategic Partnership with Takeda Pharmaceutical**: Innovent Biologics has entered into a strategic collaboration with Takeda Pharmaceutical, involving an upfront payment exceeding $1 billion, aimed at co-developing and commercializing innovative oncology therapies. This marks a significant step in Innovent's globalization strategy and enhances its global development and commercialization capabilities [2][3][8] 2. **Sales and Growth Targets**: Innovent aims to achieve sales of 20 billion RMB by 2027 and to become a leading global biopharmaceutical company by 2030, with a goal of having 15 globally registered clinical research products [2][4] 3. **Key Projects in Development**: The collaboration includes three main projects: - **363 (PD-1/L-2 molecule)**: Currently in registration studies in China and advancing international multi-center clinical trials - **3,343 (Claudin 18.2 ADC)**: Showing potential in pancreatic cancer treatment - **3,001 (ADC project)**: An option deal structure project [2][10][11] 4. **Financial Health**: Innovent has a robust financial position, with over $2 billion in cash and positive cash flow from its Chinese operations, enabling it to support its international expansion plans [4][20] 5. **Internationalization Efforts**: Innovent has established a research lab in the San Francisco Bay Area, which serves as its U.S. headquarters, and has a team of over 100 R&D personnel in the U.S. The company plans to expand this team further to support multiple products and international registration studies [6] 6. **Takeda's Advantages**: Takeda brings extensive pharmaceutical experience and resources, with projected revenues of $30 billion in 2024, and a strong R&D team of 4,500 personnel. This partnership is expected to accelerate Innovent's globalization process [2][7][19] 7. **Clinical Development Plans**: The development plans for the 363 and 343 products will continue as previously outlined, focusing on expanding their applications in various cancers, including colorectal and non-small cell lung cancer [16][18] 8. **Future Expectations**: Both companies are optimistic about the potential of the 363 and 343 projects, which are expected to revolutionize treatment options in their respective areas. The collaboration is seen as a foundation for deeper future cooperation [13][14] 9. **Budget and Investment Strategy**: Innovent plans to increase its investment in international clinical trials while balancing risk and return. The company will adopt a proof of concept (POC) approach before advancing to global Phase III trials, ensuring efficient investment returns [20] Other Important but Overlooked Content - **Regulatory Recognition**: The 363 molecule has received Breakthrough Therapy Designation (BTD) and Fast Track Designation (FTD) from regulatory authorities, indicating its potential significance in the market [12] - **Market Focus**: Innovent is particularly focused on expanding its presence in the U.S. market, which is a key component of its overall strategy [5][20] - **Collaboration Rationale**: The choice of Takeda as a partner was influenced by their strong commitment to the collaboration, alignment in clinical development plans, and their extensive experience in oncology [9][15]

Core Viewpoint - The company, Haitai Biotech (300683.SZ), announced plans to initiate the preparatory work for issuing H-shares and listing on the Hong Kong Stock Exchange by October 22, 2025, aiming to enhance its global strategy and accelerate overseas business development [1] Group 1: Strategic Intent - The company aims to deepen its global strategy and enhance its international brand image through the issuance of H-shares [1] - The move is intended to create a diversified capital operation platform [1] Group 2: Implementation Details - The company plans to discuss specific implementation steps with intermediary institutions, although details are not yet finalized [1] - The issuance and listing of H-shares will require approval from the board of directors, shareholders, and relevant government and regulatory agencies, indicating significant uncertainty in the process [1]

Core Viewpoint - The article discusses the significant turnaround of Lingyi Zhizao (领益智造) from past financial troubles to projected strong growth, alongside plans for an H-share issuance to enhance its international strategy and competitiveness [3][9]. Group 1: Financial Performance - For the first three quarters of 2025, Lingyi Zhizao expects a net profit attributable to shareholders of 1.89-2.12 billion, representing a year-on-year growth of 34.1%-50.4% [5][6]. - The net profit after deducting stock incentive expenses is projected to be 2.13-2.36 billion, with a growth of 48.62%-64.67% compared to the previous year [6]. - The net profit after excluding non-recurring gains and losses is anticipated to be 1.46-1.69 billion, reflecting a growth of 23.04%-42.42% year-on-year [6]. Group 2: Strategic Developments - Lingyi Zhizao announced plans to issue H-shares and list on the Hong Kong Stock Exchange by the end of September, aiming to further implement its international strategy and enhance its overseas business layout [7][9]. - The company seeks to broaden its merger and financing channels, increase international visibility, and improve overall competitiveness through this strategic move [7].